We are well-aligned to capitalise on the CDMO opportunity - Express Pharma

Lupin Manufacturing Solutions Repositions Assets and Leverages India’s API Ecosystem for CDMO Growth

Lupin Manufacturing Solutions (LMS) is strategically al […] The post Lupin Manufacturing Solutions Repositions Assets and Leverages India’s API Ecosystem for CDMO Growth first appeared on GeneOnline News. The post Lupin Manufacturing Solutions Repositions Assets and Leverages India’s API Ecosystem for CDMO Growth appeared first on GeneOnline News.

We are well-aligned to capitalise on the CDMO opportunity - Express Pharma

India may today account for less than 2–3 per cent of the pharma CDMO market today but has the potential to grow from $3.5 billion to $25 billion. Dr Abdelaziz Toumi, CEO, Lupin Manufacturing Solutions (LMS), explains to Viveka Roychowdhury how LMS is aligning long-term strategies, repositioning key assets, lining up investments in new modalities and leveraging India’s API ecosystem to capitalise on this opportunity. He also believes that while …